Evidence map›Paper›PMID 30171065›Full record

ReviewGut2019

Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.

Huikuan Chu, Yi Duan, Ling Yang, Bernd Schnabl

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Gut, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05448144 (Alterations of Gut Microbiota and Metabolites in Asian Patients With Alcohol-associated Liver Disease), which is not on this map. Cited by 179 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
179citing papers in PubMed, 4 pooled it
23.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05448144 unknown statusnot on this mapstarted 2022, after this paper: background citation

Alterations of Gut Microbiota and Metabolites in Asian Patients With Alcohol-associated Liver Disease

TypeobservationalSponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyRan2022 to 2024Enrolled200ConditionsLiver Disease, Alcohol-Related, Gut MicrobiotaArmsCollect stool and blood samples from patients
3 · Its place in the literature

Who cites it

179 citing papers in PubMed, 4 syntheses or guidelines pooled it, 347 citations in OpenAlex.

  1. Pooled it
  2. Vitamin E for people with non-alcoholic fatty liver disease.The Cochrane database of systematic reviews · 2024
    Pooled it
  3. Pooled it
  4. Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis.Liver international : official journal of the International Association for the Study of the Liver · 2020
    Pooled it
  5. Trial
  6. Trial
  7. Observational
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Diet supplementation with the macroalgaeFrontiers in nutrition · 2026
    Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

119 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Huikuan ChuDivision of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yi DuanDepartment of Medicine, University of California San Diego, San Diego, California, USA.
Ling YangDivision of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Bernd SchnablDepartment of Medicine, University of California San Diego, San Diego, California, USA.
Huazhong University of Science and Technology · CNVA San Diego Healthcare System · US

Funding

The Role of the Intestinal Mycobiome in Alcoholic Liver DiseaseR01AA024726 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2018 to 2026
$3.9M
Microbiome and intestinal innate immune response in alcoholic liver diseaseR01AA020703 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SCHNABL, BERND G. · 2011 to 2020
$3.6M
Microbiome as Therapeutic Target in Alcoholic HepatitisU01AA021856 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRENNER, DAVID A., SCHNABL, BERND G. · 2013 to 2017
$2.1M
NIAAA NIH HHS R01 AA020703NIAAA NIH HHS R01 AA024726NIAAA NIH HHS U01 AA021856
6 · The paper itself

Abstract

The spectrum of non-alcoholic fatty liver disease (NAFLD) ranges from simple hepatic steatosis, commonly associated with obesity, to non-alcoholic steatohepatitis, which can progress to fibrosis, cirrhosis and hepatocellular carcinoma. NAFLD pathophysiology involves environmental, genetic and metabolic factors, as well as changes in the intestinal microbiota and their products. Dysfunction of the intestinal barrier can contribute to NAFLD development and progression. Although there are technical limitations in assessing intestinal permeability in humans and the number of patients in these studies is rather small, fewer than half of the patients have increased intestinal permeability and translocation of bacterial products. Microbe-derived metabolites and the signalling pathways they affect might play more important roles in development of NAFLD. We review the microbial metabolites that contribute to the development of NAFLD, such as trimethylamine, bile acids, short-chain fatty acids and ethanol. We discuss the mechanisms by which metabolites produced by microbes might affect disease progression and/or serve as therapeutic targets or biomarkers for NAFLD.

Indexed as

Gastrointestinal MicrobiomeBile Acids and SaltsDisease ProgressionDysbiosisEthanolFatty Acids, VolatileHumansMethylaminesNon-alcoholic Fatty Liver DiseaseRisk FactorsSignal TransductionBile Acids and SaltsEthanolFatty Acids, VolatileMethylaminestrimethylamineintestinal bacteriaintestinal barrier functionnonalcoholic steatohepatitis

Identifiers

PMID30171065
OpenAlexW2888829195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.